Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hagiwara, Hiroko ^a,b   Iyo, Masaomi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; PHENAZINE METHOSULFATE; RACEMASE; SERINE; SERINE RACEMASE; UNCLASSIFIED DRUG;

ADULT ANIMAL; ADULTHOOD; AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; COGNITION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; JUVENILE ANIMAL; LOCOMOTION; MALE; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PREPULSE INHIBITION; PRODROMAL SYMPTOM; PROPHYLAXIS; RECOGNITION; SCHIZOPHRENIA;

ACOUSTIC STIMULATION; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; CEREBELLUM; FEMALE; FRONTAL LOBE; LOCOMOTION; MALE; METHYLPHENAZONIUM METHOSULFATE; MICE; RACEMASES AND EPIMERASES; SCHIZOPHRENIA; SERINE; STARTLE REACTION;

MUS;

EID: 84876450922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062438     Document Type: Article

References (70)

1. Javitt DC, Zukin SR, (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
2. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, et al. (1999) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7: 125-143.
3. Coyle JT, Tsai G, (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174: 32-38.
4. Javitt DC, Coyle JT, (2004) Decoding schizophrenia. Sci Am 290: 48-55.
5. Hashimoto K, Shimizu E, Iyo M, (2005) Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 1: 151-163.
6. Hashimoto K, (2006) The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin Psychopharmacol Neurosci 4: 3-10.
7. Wolosker H, Sheth KN, Takahashi M, Mothet JP, Brady RO Jr, et al. (1999) Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 96: 721-725.
8. Wolosker H, Blackshaw S, Snyder SH, (1999) Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci USA 96: 13409-13414.
9. Wolosker H, Mori H, (2012) Serine racemase: an unconventional enzyme for an unconventional transmitter. Amino Acids 43: 1895-1904.
10. Inoue R, Hashimoto K, Harai T, Mori H, (2008) NMDA- and β-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J Neurosci 28: 14486-14491.
11. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, et al. (2009) Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 14: 719-727.
12. Horio M, Kohno M, Fujita Y, Ishima T, Inoue R, et al. (2011) Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem Int 59: 853-859.
13. Horio M, Mori H, Hashimoto K (in press) Is D-cycloserine a pro-drug for D-serine in the brain? Biol Psychiatry 2012 Aug 7. [Epub ahead of print].
14. Hashimoto A, Nishikawa T, Oka T, Takahashi K, (1993) Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem 60: 783-786.
15. Schell MJ, Brady RO Jr, Molliver ME, Snyder SH, (1997) D-Serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptor. J Neurosci 17: 1604-1615.
16. Wang LZ, Zhu XZ, (2003) Spatiotemporal relationships among D-serine, serine racemase, and D-amino acid oxidase during mouse postnatal development. Acta Pharmacol Sci 24: 965-974.
17. Ferraris DV, Tsukamoto T, (2011) Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des 17: 103-111.
18. Labrie V, Wong AH, Roder JC, (2012) Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 62: 1484-1503.
19. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D, (2012) Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull 38: 958-966.
20. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, et al. (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60: 572-576.
21. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, et al. (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 57: 1493-1503.
22. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, et al. (2005) Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29: 767-769.
23. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, et al. (2007) A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90: 41-51.
24. Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, et al. (2012) Plasma levels of D-serine in Brazillian individuals with schizophrenia. Schizophr Res 142: 93-87.
25. Tsai G, Yang P, Chung LC, Lange L, Coyle JT, (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44: 1081-1089.
26. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, et al. (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57: 577-585.
27. Tsai GE, Lin PY, (2010) Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia. A critical review and meta-analysis. Curr Pham Des 16: 522-537.
28. Verrall L, Walker A, Rawlings N, Benzel I, Kew JNC, et al. (2007) D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26: 1657-1669.
29. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R, (2008) Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 101: 76-83.
30. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99: 13675-13680.
31. Kvajo M, Dhilla A, Swor DE, Karayiorgou M, Gogos JA, (2008) Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 13: 685-696.
32. Detetra-Wadleigh SD, McMahon FJ, (2006) G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 60: 106-114.
33. Weinberger DR, (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669.
34. Wyatt RJ, (1996) Neurodevelopmental abnormalities and schizophrenia. A family affair. Arch Gen Psychiatry 53: 11-15.
35. McGrath JJ, Féron FP, Burne TH, Mackay-Sim A, Eyles DW, (2003) The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann Med 35: 86-93.
36. Kim PM, Aizawa H, Kim PS, Huang AS, Wickramasinghe SR, et al. (2005) Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci USA 102: 2105-2110.
37. Fukushima T, Kawai J, Imai K, Toyo'oka T, (2004) Simultaneous determination of D- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed Chromatogr 18: 813-819.
38. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, et al. (2005) Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 5: 6.
39. Hashimoto K, Sawa A, Iyo M, (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62: 1310-1316.
40. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, et al. (2006) Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59: 546-554.
41. Zhang L, Shirayama Y, Iyo M, Hashimoto K, (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004-2010.
42. Hagiwara H, Iyo M, Hashimoto K, (2009) Mithramycin protects dopaminergic neurotoxicity in mouse brain after administration of methamphetamine. Brain Res 1301: 189-196.
43. Hashimoto K, Fujita Y, Shimizu E, Iyo M, (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519: 114-117.
44. Hashimoto K, Fujita Y, Iyo M, (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: Role of sigma-1 receptors. Neuropsychopharmacology 32: 514-521.
45. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, et al. (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63: 92-97.
46. Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, et al. (2009) Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 65: 1103-1106.
47. Sams-Dodd F, (1998) Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19: 18-25.
48. Mandillo S, Rinaldi A, Oliverio A, Mele A, (2003) Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14: 533-544.
49. Zakzanis KK, (1998) Neuropsychological correlates of positive vs. negative schizophrenic symptomatology. Schizophr Res 29: 227-233.
50. Hashimoto K, Fujita Y, Shimizu E, Iyo M, (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519: 114-117.
51. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M, (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 18: 414-421.
52. Braff DL, Geyer MA, (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47: 181-188.
53. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, et al. (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50: 884-897.
54. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B, (2004) Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 68: 37-48.
55. Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, et al. (2011) Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Am J Psychiatry 168: 806-813.
56. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, et al. (2009) Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 70: 1206-1212.
57. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, et al. (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69: 562-571.
58. Sabbag R, Levin R, Edelman S, Heresco-Levy U, (2011) Preventive pharmacological treatment - An evolving new concept in schizophrenia. Isr J Psychiatry Relat Sci 48: 82-90.
59. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR,et al. (in press) Glycine treatment of the risk syndrome for psychosis: Report of two pilots studies. Eur Neuropsychopharmacol 2012 Oct 19. doi:pii: S0924-977X(12)00272-6. 10.1016/j.euroneuro.2012.09.008. [Epub ahead of print].
60. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, et al. (2010) High dose of D-serine in the treatment of schizophrenia. Schizophr Res 121: 125-130.
61. Hashimoto K, (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61: 105-123.
62. Maekawa T, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, et al. (2010) Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of Shmt1 (SHMT1) in mice and schizophrenia. J Neurochem 115: 1374-1385.
63. Hashimoto K, Malchow B, Falkai P, Schmitt P (in press) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013 Mar 1. [Epub ahead of print].
64. Sucher NJ, Lipton SA, (1991) Redox modulatory site of the NMDA receptor-channel complex: Regulation by oxidized glutathione. J Neurosci Res 30: 582-591.
65. Kohr G, Eckardt S, Luddens H, Monyer H, Seeburg PH, (1994) NMDA receptor channels: Subunit-specific potentiation by reducing agents. Neuron 12: 1031-1040.
66. Varga V, Jenei Z, Janaky R, Saransaari P, Oja SS, (1997) Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Neurochem Res 22: 1165-1171.
67. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, et al. (2008) Negative correlation between brain glutathione levels and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 3: e1944.
68. Hashimoto K, (2008) Correspondence: Regarding "N-Acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial". Biol Psychiatry 64: e1.
69. Matsuzawa D, Hashimoto K, (2011) Magnetic resonance spectroscopy study of antioxidant defense system in schizophrenia. Antioxi Redox Sig15: 2057-2065.
70. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M, (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19: 220-230.